Qualigen therapeutics' pan-ras inhibitor featured in two abstracts at american society for clinical oncology (asco) 2022 annual meeting

Abstracts highlight in vitro and in vivo activity of qualigen's pan-ras inhibitor in (1) pancreatic cancer, and (2) malignant peripheral nerve sheath tumors

QLGN Ratings Summary

QLGN Quant Ranking